Sign In

Jan D'Alvise

Chief Executive Officer (CEO) - Board Director ⇨ Driving Innovation, Fostering Teamwork, Raising Capital, and Maximizing Commercial Potential

Professional Background

Jan D'Alvise is a highly respected CEO and Board Director with over 25 years of experience in the life sciences industry, encompassing pharmaceuticals, medical devices, diagnostics, and discovery and translational research. Known for her strategic foresight and innovative mindset, D'Alvise has carved a niche in corporate strategic planning and operational execution. Her expertise extends to product and program development, as well as commercialization, where she expertly translates market and medical needs into precise technical product specifications.

D'Alvise is recognized as a disciplined financial steward with a successful track record in both large corporations and startups. She excels in building, managing, and funding startups while also adeptly turning around struggling companies. With a background in financial planning, corporate development, and business strategies, D'Alvise has proven her capabilities in fundraising, having secured over $550 million in combined equity, debt, and strategic capital to propel organizational growth and development.

Education and Achievements

D'Alvise began her educational journey with a Bachelor of Science in Biochemistry from Michigan Technological University, where she laid the groundwork for her future endeavors in the life sciences field. She further pursued her business acumen through coursework in an MBA program at the University of Michigan, equipping her with vital skills necessary for leadership in competitive corporate landscapes.

Throughout her esteemed career, Jan has achieved remarkable milestones, underscoring her reputation as a visionary leader. These highlights include:

  • Raising more than $150 million in public markets, demonstrating her expertise in capital acquisition and financial management.
  • Leading Acasti Pharma Inc. through a successful turnaround following a Phase 3 program failure, as well as completing a strategic acquisition of Grace Therapeutics valued at $80 million, thereby advancing two rare and orphan drug programs from IND to Phase 3 in just 18 months.
  • Co-founding and leading two successful startup companies, NuGEN Technologies and METRIKA, which raised over $80 million from concept to successful commercialization, ultimately leading to their acquisition by major multinational companies.
  • Turning around the medical device company, Gish Biomedical, achieving break-even within six months and orchestrating a profitable sale of the company to Sorin Group, a leading global entity in cardiopulmonary medical devices.

Notable Contributions

Jan has effectively utilized her expertise in strategic planning to oversee the sale of the struggling non-profit cancer institute, Sidney Kimmel Cancer Center (SKCC), to the Sanford Burnham Prebys Institute, valuing the M&A transaction at over $40 million while preserving its scientific personnel and grant programs.

Additionally, she has achieved combined upfronts exceeding $250 million through executing numerous out-licensing, co-development, and commercialization transactions, predominantly in the clinical diagnostic sector. This substantial achievement further solidifies her standing as a prominent figure in the life sciences industry.

Achievements

Jan D'Alvise possesses numerous notable achievements in her illustrious career, including:

  • Successfully orchestrating capital raises exceeding $250M from public and private markets, showcasing her adeptness in fundraising and financial strategy.
  • Leading the turnaround of Acasti Pharma after a challenging Phase 3 failure and strategically acquiring Grace Therapeutics to enhance their pipeline of orphan drug programs.
  • Co-founding and guiding startups like NuGEN and METRIKA from inception to acquisition, securing considerable funding along the way.
  • Achieving a break-even point for Gish Biomedical within six months and orchestrating its profitable sale to a global leader in cardiopulmonary medical devices.
  • Skillfully managing the strategic sale of SKCC in a manner that preserved invaluable scientific resources and personnel.

tags':['CEO','board director','life sciences','medical devices','pharmaceuticals','diagnostics','corporate strategy','operational execution','product development','commercialization','financial planning','business development','fundraising','capital acquisition','emerging market opportunities','strategic thinker','clinical diagnostics','startup management','company turnaround','market dynamics'],

questions':['What strategies has Jan D'Alvise employed to successfully raise over $550 million in capital throughout her career?','How did Jan D'Alvise lead Acasti Pharma Inc. through its significant turnaround after a Phase 3 program failure?','What key factors contributed to the successful commercialization of startups founded by Jan D'Alvise such as NuGEN and METRIKA?','In what ways has Jan D'Alvise influenced the life sciences industry through her roles as a CEO and Board Director?',

Jan D'Alvise
Add to my network

Location

San Diego County, California, United States